Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 43, Issue 5, 2014, Pages 371-373

  Ruge, Toralph ^a   Sodergren A ^b   Wallberg Jonsson S ^b   Larsson, A ^c   Arnlov J ^d,e  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATHEPSIN L; CATHEPSIN S; CATHEPSIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DAS28; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SWEDEN; ARTHRITIS, RHEUMATOID; ARTICULAR CARTILAGE; BLOOD; CASE CONTROL STUDY; DISABILITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SYNOVIUM;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; CATHEPSIN L; CATHEPSINS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWEDEN; SYNOVIAL MEMBRANE;

EID: 84921745136     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.882979     Document Type: Article

References (20)

1. Pozgan U, Caglic D, Rozman B, Nagase H, Turk V, Turk B. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010;391:571-9.
2. Cunnane G, FitzGerald O, Hummel KM, Gay RE, Gay S, Bresnihan B. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford) 1999;38:34-42.
3. Yasuda Y, Kleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005;57:973-93.
4. Takahashi K, Ueno T, Tanida I, Minematsu-Ikeguchi N, Murata M, Kominami E. Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. Biol Pharm Bull 2009;32:475-9.
5. Innala L, Moller B, Ljung L, Magnusson S, Smedby T, Sodergren A, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13:R131.
6. Sodergren A, Karp K, Boman K, Eriksson C, Lundstrom E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Iwata Y, Mort JS, Tateishi H, Lee ER. Macrophage cathepsin L, a factor in the erosion of subchondral bone in rheumatoid arthritis. Arthritis Rheum 1997;40:499-509.
10. Schurigt U, Stopfel N, Huckel M, Pfirschke C, Wiederanders B, Brauer R. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther 2005;7:R174-88.
11. Nguyen Q, Mort JS, Roughley PJ. Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B. Biochem J 1990;266:569-73.
12. Hou WS, Li Z, Buttner FH, Bartnik E, Bromme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 2003;384:891-7.
13. Li Z, Yasuda Y, Li W, Bogyo M, Katz N, Gordon RE, et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J Biol Chem 2004;279:5470-9.
14. Schurigt U, Eilenstein R, Gajda M, Leipner C, Sevenich L, Reinheckel T, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res 2012;61:1021-9.
15. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-17.
16. Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 2011;36:201-9.
17. Weidauer E, Yasuda Y, Biswal BK, Cherny M, James MN, Bromme D. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol Chem 2007;388:331-6.
18. Chircorian A, Barrios AM. Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg Med Chem Lett 2004;14:5113-16.
19. Keyszer G, Lambiri I, Keysser M, Keysser C, Nagel R, Burmester GR, et al. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity. Z Rheumatol 1998;57:392-8.
20. Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001;159:2167-77.